CDK 4/6 Inhibitors in HR+/HER2- Breast Cancer – Hoboken, NJ
Hoboken University Medical Center 308 Willow Ave, Hoboken, NJ, United StatesThis program will review the use of CDK 4/6 inhibitors in the treatment of HR+/HER2-negative breast cancer and the management of treatment-related adverse events.